JP2021523935A - チオフェン誘導体の固体形態 - Google Patents

チオフェン誘導体の固体形態 Download PDF

Info

Publication number
JP2021523935A
JP2021523935A JP2021510510A JP2021510510A JP2021523935A JP 2021523935 A JP2021523935 A JP 2021523935A JP 2021510510 A JP2021510510 A JP 2021510510A JP 2021510510 A JP2021510510 A JP 2021510510A JP 2021523935 A JP2021523935 A JP 2021523935A
Authority
JP
Japan
Prior art keywords
ethyl
ethoxy
methoxyphenyl
methylsulfonyl
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510510A
Other languages
English (en)
Japanese (ja)
Inventor
ジャン・ドンレイ
ワン・リーユー
リィ・シンウェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Hemay Pharmaceutical Co Ltd
Original Assignee
Tianjin Hemay Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical Co Ltd filed Critical Tianjin Hemay Pharmaceutical Co Ltd
Publication of JP2021523935A publication Critical patent/JP2021523935A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
JP2021510510A 2018-05-02 2019-04-30 チオフェン誘導体の固体形態 Pending JP2021523935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810407741.X 2018-05-02
CN201810407741 2018-05-02
PCT/CN2019/085352 WO2019210867A1 (zh) 2018-05-02 2019-04-30 噻吩衍生物的固体形式

Publications (1)

Publication Number Publication Date
JP2021523935A true JP2021523935A (ja) 2021-09-09

Family

ID=68386284

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2021510510A Pending JP2021523935A (ja) 2018-05-02 2019-04-30 チオフェン誘導体の固体形態
JP2021510509A Active JP7542523B2 (ja) 2018-05-02 2019-04-30 チオフェン誘導体の結晶形
JP2020561687A Active JP7481263B2 (ja) 2018-05-02 2019-04-30 チオフェン誘導体の結晶形
JP2020561683A Active JP7477459B2 (ja) 2018-05-02 2019-04-30 チオフェン誘導体の結晶形
JP2023204100A Withdrawn JP2024026251A (ja) 2018-05-02 2023-12-01 チオフェン誘導体の結晶形

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021510509A Active JP7542523B2 (ja) 2018-05-02 2019-04-30 チオフェン誘導体の結晶形
JP2020561687A Active JP7481263B2 (ja) 2018-05-02 2019-04-30 チオフェン誘導体の結晶形
JP2020561683A Active JP7477459B2 (ja) 2018-05-02 2019-04-30 チオフェン誘導体の結晶形
JP2023204100A Withdrawn JP2024026251A (ja) 2018-05-02 2023-12-01 チオフェン誘導体の結晶形

Country Status (14)

Country Link
US (4) US11396518B2 (https=)
EP (5) EP3789389B1 (https=)
JP (5) JP2021523935A (https=)
KR (4) KR102839924B1 (https=)
CN (7) CN116813637A (https=)
AU (4) AU2019263865B2 (https=)
BR (4) BR112020021976A2 (https=)
CA (4) CA3213055A1 (https=)
DK (1) DK3789389T3 (https=)
ES (1) ES3047059T3 (https=)
FI (1) FI3789389T3 (https=)
PL (1) PL3789389T3 (https=)
PT (1) PT3789389T (https=)
WO (4) WO2019210864A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523890A (ja) * 2018-05-02 2021-09-09 天津合美医▲薬▼科技有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． チオフェン誘導体の結晶形

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526731A (ja) * 2009-05-14 2012-11-01 天津和美生物技術有限公司 チオフェン誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
WO2012000499A1 (en) 2010-06-30 2012-01-05 Leo Pharma A/S New polymorphic form of a calcimimetic compound
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
IL297649A (en) 2014-07-18 2022-12-01 Green Cross Corp Crystalline form of 5-chloro-m ({5)-2-oxo-3-[4-(6,5-dihydro-4-[1,2,4]triazin-1yl)phenyl}-1,3- Oxazolidine-5-yl} methyl) thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
US10570147B2 (en) 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
ES2979170T3 (es) * 2017-06-30 2024-09-24 Trophy Aparato de formación de imágenes dentales extraorales con detección de accesorios para el posicionamiento del paciente
CN116813637A (zh) * 2018-05-02 2023-09-29 天津合美医药科技有限公司 噻吩衍生物的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526731A (ja) * 2009-05-14 2012-11-01 天津和美生物技術有限公司 チオフェン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杉本功、高橋嘉輝: "溶媒和物、非晶質固体と医薬品製剤", 紛体工学会誌, vol. 22(2), JPN6017004373, 1985, pages 85 - 97, ISSN: 0004889724 *
米持悦生: "医薬品原薬及び製剤のバルク状態分析の重要性", SCAS NEWS, vol. 2004-II, JPN6017004374, 2004, pages 3 - 6, ISSN: 0004889723 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021523890A (ja) * 2018-05-02 2021-09-09 天津合美医▲薬▼科技有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． チオフェン誘導体の結晶形
JP2021523891A (ja) * 2018-05-02 2021-09-09 天津合美医▲薬▼科技有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． チオフェン誘導体の結晶形
JP7477459B2 (ja) 2018-05-02 2024-05-01 天津合美医▲薬▼科技有限公司 チオフェン誘導体の結晶形
JP7481263B2 (ja) 2018-05-02 2024-05-10 天津合美医▲薬▼科技有限公司 チオフェン誘導体の結晶形

Also Published As

Publication number Publication date
EP3789389A4 (en) 2022-01-26
EP4335515A2 (en) 2024-03-13
KR20210022557A (ko) 2021-03-03
BR112020022190A2 (pt) 2021-02-02
EP3789389A1 (en) 2021-03-10
CN110437250B (zh) 2023-06-23
WO2019210864A1 (zh) 2019-11-07
CN110437250A (zh) 2019-11-12
EP3789387A4 (en) 2021-06-30
AU2019262284A1 (en) 2020-12-24
AU2019262282B2 (en) 2022-04-28
WO2019210865A1 (zh) 2019-11-07
KR102701245B1 (ko) 2024-08-30
EP3789388B1 (en) 2024-01-24
JP7477459B2 (ja) 2024-05-01
US20210139498A1 (en) 2021-05-13
DK3789389T3 (da) 2025-11-10
CN116813637A (zh) 2023-09-29
BR112020022186A2 (pt) 2021-02-02
EP3789387B1 (en) 2024-02-28
EP3789387A1 (en) 2021-03-10
AU2019262286B2 (en) 2022-08-11
EP3789388A4 (en) 2021-06-09
US20210380600A1 (en) 2021-12-09
KR102839924B1 (ko) 2025-07-29
US20210230181A1 (en) 2021-07-29
AU2019263865A1 (en) 2020-12-24
CN110437251A (zh) 2019-11-12
CA3099071A1 (en) 2019-11-07
KR20210025001A (ko) 2021-03-08
CN110437249A (zh) 2019-11-12
CN110437251B (zh) 2023-07-21
AU2019262282A1 (en) 2020-11-12
US12227514B2 (en) 2025-02-18
US20210238191A1 (en) 2021-08-05
CA3213055A1 (en) 2019-11-07
BR112020021976A2 (pt) 2021-01-26
CA3098927C (en) 2023-10-03
US11396518B2 (en) 2022-07-26
AU2019262286A1 (en) 2020-11-12
KR102686835B1 (ko) 2024-07-22
CN116854705A (zh) 2023-10-10
JP2021523890A (ja) 2021-09-09
EP4335515A3 (en) 2024-07-03
CN116947878A (zh) 2023-10-27
PL3789389T3 (pl) 2026-03-16
EP3800190A4 (en) 2022-01-26
US11274104B2 (en) 2022-03-15
BR112020021945A2 (pt) 2021-01-26
CA3098931C (en) 2023-10-24
CN110437249B (zh) 2023-07-21
AU2019263865B2 (en) 2022-01-27
WO2019210869A1 (zh) 2019-11-07
FI3789389T3 (fi) 2025-11-19
EP3800190A1 (en) 2021-04-07
JP2021523891A (ja) 2021-09-09
CA3098931A1 (en) 2019-11-07
EP3789388A1 (en) 2021-03-10
ES3047059T3 (en) 2025-12-03
US12180222B2 (en) 2024-12-31
CA3098927A1 (en) 2019-11-07
KR20210025000A (ko) 2021-03-08
WO2019210867A1 (zh) 2019-11-07
JP7481263B2 (ja) 2024-05-10
CA3099072A1 (en) 2019-11-07
JP2024026251A (ja) 2024-02-28
JP7542523B2 (ja) 2024-08-30
CN116836178A (zh) 2023-10-03
JP2021522348A (ja) 2021-08-30
KR20210022556A (ko) 2021-03-03
PT3789389T (pt) 2025-12-17
EP3789389B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
JP2024026251A (ja) チオフェン誘導体の結晶形
CA3099071C (en) Crystal forms of thiophene derivatives
HK40047648B (en) Crystalline form of (s)‑n‑[5‑[1‑(3‑ethoxy‑4‑methoxyphenyl)‑2‑(methylsulfonyl)ethyl]‑4,6‑dioxo‑5,6‑dihydro‑4h‑thieno[3,4‑c]pyrrole‑1‑yl]acetamide
HK40048511A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048512B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048512A (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40048511B (en) Crystal form of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1-yl]acetamide
HK40047649A (en) Solid form of thiophene derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004